The Acute Heart Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Heart Failure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Acute Heart Failure by ten companies/universities/institutes. The top development phase for Acute Heart Failure is phase i with three drugs in that stage. The Acute Heart Failure pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Acute Heart Failure pipeline products market are: Windtree Therapeutics, GEXVal and 4TEEN4 Pharmaceuticals.
The key targets in the Acute Heart Failure pipeline products market include Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2, Serotransferrin, and Sodium/Glucose Cotransporter 2.
The key mechanisms of action in the Acute Heart Failure pipeline product include Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2 Activator with two drugs in Phase II. The Acute Heart Failure pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Acute Heart Failure pipeline products market including Small Molecule, and Monoclonal Antibody.
Acute Heart Failure overview
Acute heart failure (AHF) is a critical medical condition characterized by a sudden onset or rapid worsening of symptoms related to the heart’s inability to pump blood effectively. This leads to insufficient oxygen delivery to tissues and organs. AHF can manifest as either new-onset heart failure or exacerbation of chronic heart failure. Common symptoms include shortness of breath, fatigue, and fluid retention, often resulting in pulmonary congestion and peripheral edema. Various factors such as coronary artery disease, hypertension, or infections can precipitate AHF. Prompt diagnosis, often through clinical evaluation and imaging, guides immediate interventions, including medications and, in severe cases, mechanical support or surgical interventions to optimize cardiac function and improve outcomes.
For a complete picture of Acute Heart Failure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
